FocalTherics (NASDAQ:FOCL) CFO Purchases 5,000 Shares

August 18, 2026 by InsiderTrades.com

Key Points

Director Lance Willsey bought 50,000 FocalTherics shares at an average of $4.75 each, investing $237,500 and increasing his ownership by 4.03% to 1,291,780 shares.
FocalTherics reported a quarterly loss of $0.39 per share, missing estimates by $0.19, despite revenue of $13.2 million. The company posted a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share.
Shares opened at $4.36 after falling 8.4%, while analyst opinions remained mixed; the stock carries a consensus “Hold” rating with a $7.75 price target.

FocalTherics (NASDAQ:FOCL - Get Free Report) CFO Kenneth Mobeck purchased 5,000 shares of the business's stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the purchase, the chief financial officer owned 181,610 shares of the company's stock, valued at approximately $862,647.50. This trade represents a 2.83% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

FocalTherics Price Performance

FOCL stock opened at $4.36 on Tuesday. FocalTherics has a 1-year low of $1.30 and a 1-year high of $6.40. The company has a 50-day moving average price of $5.38. The company has a market capitalization of $163.41 million, a P/E ratio of -4.23 and a beta of -0.04. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99.

FocalTherics (NASDAQ:FOCL - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). The business had revenue of $13.20 million for the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. On average, analysts anticipate that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of FOCL. SmartHarvest Portfolios LLC purchased a new stake in FocalTherics during the first quarter valued at approximately $38,000. Lido Advisors LLC purchased a new position in FocalTherics in the first quarter worth $40,000. Kovack Advisors Inc. acquired a new position in shares of FocalTherics during the fourth quarter worth $53,000. Leonteq Securities AG acquired a new position in shares of FocalTherics during the fourth quarter worth $313,000. Finally, Flax Pond Capital LLC purchased a new stake in shares of FocalTherics during the 4th quarter valued at $2,623,000. Institutional investors own 62.74% of the company's stock.

FocalTherics News Summary

Here are the key news stories impacting FocalTherics this week:

Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on FOCL shares. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the company an "outperform" rating in a research note on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. Piper Sandler reiterated a "neutral" rating and issued a $4.00 price target on shares of FocalTherics in a report on Friday. Finally, Wall Street Zen lowered FocalTherics from a "hold" rating to a "sell" rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $7.75.

Get Our Latest Report on FOCL

FocalTherics Company Profile

(Get Free Report)

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.